EBR Systems, Inc.

EBR Systems, Inc. develops and commercializes the WiSE CRT System, a leadless cardiac resynchronization therapy platform used to help treat heart failure patients who need pacing support. The company is transitioning from development to U.S. commercialization after FDA approval in April 2025, with its business centered on hospital adoption, reimbursement coverage, and clinical workflow integration.

−2 825,2 %

30,3 %

−3 015,3 %

5.20

4.22

— EBR Systems, Inc.
	%
WiSE CRT System	100% The company's core commercial product for cardiac resynchronization therapy using leadless pacing technology.

EBR sells primarily to hospitals and the physicians who implant and use the WiSE CRT System in cardiac procedures...

U.S. hospital customersprimary
Hospitals that purchase and use WiSE CRT for approved cardiac procedures, driven by clinical demand and reimbursement coverage.
Implanting physicians and electrophysiology teamsprimary
Physicians and clinical teams who decide whether to adopt the technology and how frequently it is used per site.
International hospital marketssecondary
Hospitals in Australia, the United Kingdom and the European Union targeted for future launch once approvals and coverage are in place.

The company is currently focused on the United States, where WiSE received FDA approval in April 2025 and commercial...

•United States is the initial commercial market after FDA approval
•U.S. reimbursement coverage is critical to adoption and pricing
•Australia is a stated target for future OUS launch
•United Kingdom is a stated target for future OUS launch
•European Union is a stated target for future OUS launch

EBR's near-term strategy is to scale U.S. commercialization by expanding the field team, improving hospital training,...

Scale U.S. commercial launchshort-term

The company now needs to convert FDA approval into recurring hospital usage and revenue.

Improve reimbursement and market accessshort-term

Coverage determines whether hospitals can economically adopt the system at scale.

Prepare international commercializationmedium-term

OUS markets could expand the addressable market once regulatory and payment hurdles are cleared.

EBR remains a development-to-commercialization company with substantial going-concern risk and dependence on external...

critical

Going concern and financing risk

The company expects continued operating losses and negative cash flow, so it may need additional capital to fund commercialization.

Scope: Cash runway and ability to continue operations
Materiality: high

high

Single-product concentration

WiSE CRT is the only FDA-approved product, so revenue generation depends on one platform succeeding commercially.

Scope: Revenue, profitability and valuation
Materiality: high

high

Reimbursement and market-access risk

Hospitals may not adopt the system broadly without adequate CMS and payer coverage.

Scope: U.S. launch economics and procedure volume
Materiality: high

high

Regulatory compliance risk

Post-marketing FDA obligations, cGMP and reporting requirements can drive cost and create withdrawal risk if not met.

Scope: Product approval status and operating costs
Materiality: high

medium

Competitive pressure

Large, well-capitalized medtech competitors can outspend EBR on sales, evidence generation and physician engagement.

Scope: Market share and pricing
Materiality: medium

Revenue recognition on WiSE sales

Affects reported revenue timing and quarterly comparability

Going-concern assessment

Signals financing dependence and affects investor interpretation of liquidity

Stock-based compensation

Inflates operating expenses and reduces comparability of adjusted metrics

Debt and interest expense

Affects net loss and leverage analysis

EBR Systems, Inc.

Going concern and financing risk

Single-product concentration

Reimbursement and market-access risk

Regulatory compliance risk

Competitive pressure

iRhythm Holdings, Inc.

KESTRA MEDICAL TECHNOLOGIES, LTD.

Corvex, Inc.

Edwards Lifesciences Corp

NeuroPace Inc

HeartBeam, Inc.